MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Gelesis launches anti-obesity pill

Gelesis launches anti-obesity pill

By

Gelesis logo

Curbing obesity may be as simple as popping a pill before meals.

A new capsule called Attiva does just that — expanding in the stomach to significantly reduce hunger between meals and make people feel fuller, according to the results of a clinical trial released by Boston-based Gelesis Inc.

The capsule contains a super-absorbent hydrogel comprised of food components. It’s an alternative to potentially risky gastric bypass surgery. Obesity affects nearly 34 percent of American adults, according to a recent study published in the Journal of the America Medical Assn.

The capsule, classified as a medical device because it isn’t absorbed into the bloodstream like a drug, is swallowed with water. As it breaks down in the stomach, tiny hydrogel particles (about the size of a grain of salt) expand hundreds of times, creating less room for food. The enlarged particles, mixing with other food particles, swell against the stomach walls, signaling to the brain that the person is full. Afterwards, the particles — which have the same elasticity and viscosity as foods — disintegrate in the colon and pass naturally. You can see an animated demonstration of the process on the Gelesis website.

"For the first time a group was able to overcome the enormous technical hurdles in creating a super-absorbent polymer made entirely out of food," MIT Institute Professor Robert Langer said in prepared remarks. "This opens the door for entirely new uses of polymers in medicine and offers hope in treating obesity, which has become a serious health issue."

The Italian trial involved 95 normal, overweight and obese subjects with an average body mass index of 31. Before breakfast, lunch and dinner, subjects took two grams of Attiva or a placebo and were asked to fill out a questionnaire immediately, 30 minutes after and an hour after their meals. Subjects reported satieity after each meal and less hunger before dinner. The findings were presented to the American Assn. of Clinical Endocrinologists’ annual meeting today, according a press release.

In case you missed it

RSS From Medical Design & Outsourcing

  • Henry Schein investors push back on executive pay
    Nearly half of Henry Schein (Nasdaq:HSIC) shareholders who voted at this month’s annual meeting voted against the company’s pay packages for top executives, according to a new SEC filing. About 48.5% of voting shareholders voted against the company’s executive pay plan in what’s known as the Say-on-Pay vote, according to vote results of the May… […]
  • Creo Medical inks collaboration agreement with Intuitive
    Creo Medical Group (LON: CREO) announced today that it has signed a multi-year collaboration agreement with Intuitive to make certain Creo surgical technologies compatible with the surgical robotic giant’s systems. The London exchange reacted by sending CREO shares up more than 4% to 100 pence apiece by the close of trading today. As of midday… […]
  • MedTrace Pharma moves forward on 15 O-water imaging tech
    MedTrace Pharma announced the first person scanned in its Rapid-Water-Flow Phase 3 clinical trial, further testing its tech to bring 15 O-water to imaging. The first subject scan took place at Aarhus University Hospital in Denmark, using 15 O-water produced, dosed and injected through MedTrace’s P3 automated delivery system. The clinical trial aims to evaluate… […]
  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
    An unusually large share of Zimmer Biomet (NYSE:ZBH) investors voted against the orthopedics company’s pay packages for top executives at the annual shareholder meeting. About 54% of voting shareholders supported the pay packages of the company’s five top-paid executives at the May 13 meeting, according to results filed with the SEC yesterday. In 2021, nearly 93%… […]
  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
    BD (NYSE:BDX) announced that it partnered with Mitsubishi Gas Chemical Company on applying new technology to pre-fillable syringes. MGC develops the Oxycapt technology designed to integrate the best of plastic and glass for plastic syringes. BD and Tokyo-based MGC will work together to apply Oxycapt technology to the next generation of pre-fillable syringes (PFS) for advanced… […]
  • Ambu replaces CEO with new leadership
    Ambu today said it has hired board member Britt Meelby Jensen to replace CEO Juan Jose Gonzalez, effective tomorrow. “Since Juan Jose Gonzalez joined as CEO in 2019, Ambu has made good progress and achieved important milestones on the strategic transformation into the world’s largest single-use endoscopy company,” Ambu Chair Jørgen Jensen said in a… […]
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
    AdvaMed executive Abby Pratt has joined the executive committee for the Biden administration’s Joint Supply Chain Resilience Working Group, the medtech industry association said today. The working group’s members from government and industry will assist with implementation of the National Strategy for a Resilient Public Health Supply Chain. Pratt oversees supply chain issues as SVP… […]
  • Toray develops new stretchable film for medical devices
    Toray Industries has a new stretchable film based on its proprietary polymer Reactis technology, with potential applications that include robotics and biological and industrial sensors. Tokyo-based Toray said it shipped samples to customers and plans research and development efforts to commercialize the new grade of film. “Recent years have increased the potential for developing stretchable… […]
  • Google Health hires FDA’s chief digital health officer
    Former FDA Chief Digital Health Officer of Global Strategy and Innovation Bakul Patel has started a new job with Google after 13 years with the regulatory agency. Patel became senior director, global digital health strategy and regulatory for Google Health earlier this month, he said on LinkedIn. Patel recounted highlights of his “incredible journey since… […]
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says
    Two years into the COVID-19 pandemic, we know more than ever about the SARS-CoV-2 virus and how quickly it moves to ravage the human body. What remains to be seen is how the virus — and perhaps more importantly, our immune system’s response to it — will affect the health of people long after infection,… […]
  • FDA moves forward with Voluntary Improvement Program to bolster medical device quality
    Kathryn Burke, Emergo Group The U.S. Food and Drug Administration has issued new draft guidance to establish a full-blown voluntary program for improving quality-related processes in medical device manufacturing following promising results of a pilot program. The FDA guidance stems from a pilot undertaken by the agency along with the Medical Device Innovation Consortium (MDIC) in 2018.… […]

Leave a Reply